DrugPatentWatch Database Preview
Details for Patent: 9,125,908
Email this page to a colleague
Which drugs does patent 9,125,908 protect, and when does it expire?
Patent 9,125,908 protects TRINTELLIX and is included in one NDA.
This patent has eighty-eight patent family members in thirty-three countries.
Summary for Patent: 9,125,908
| Title: | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment |
| Abstract: | 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients. ##STR00001## |
| Inventor(s): | Bang-Andersen; Benny (Copenhagen S, DK), Mork; Arne (Malov, DK), Stensbol; Tine Bryan (Vaerlose, DK), Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK) |
| Assignee: | H. Lundbeck A/S (Copenhagen-Valby, DK) |
| Application Number: | 14/242,510 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,125,908 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,125,908
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | ⤷ Try it Free | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | ⤷ Try it Free | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ⤷ Try it Free | ⤷ Try it Free | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | ⤷ Try it Free | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,125,908
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2006 00824 | Jun 16, 2006 |
| Denmark | 2006 01223 | Sep 22, 2006 |
| Denmark | 2006 01384 | Oct 25, 2006 |
| Denmark | 2007 00427 | Mar 20, 2007 |
International Family Members for US Patent 9,125,908
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 061481 | ⤷ Try it Free | |||
| Argentina | 065797 | ⤷ Try it Free | |||
| Austria | 495745 | ⤷ Try it Free | |||
| Austria | 540941 | ⤷ Try it Free | |||
| Australia | 2007260355 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
